Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Discontinued Operations - Discontinued Operations (Details)

v3.10.0.1
Note 3 - Discontinued Operations - Discontinued Operations (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Accrued liabilities     $ 7,092
Liabilities associated with discontinued operations, current     $ 7,092
Lymphoseek sales revenue $ 9,663 $ 2,926,876  
Cost of goods sold 24,216 388,408  
Gross profit (14,553) 2,538,468  
Operating expenses of discontinued operation:          
Research and development 2,453 75,196 2,453 358,729  
Selling, general and administrative 820,203  
Total operating expenses 2,453 75,196 2,453 1,178,932  
(Loss) income from discontinued operations (2,453) (89,749) (2,453) 1,359,536  
Interest expense (1,718,506)  
Loss before income taxes (2,453) (89,749) (2,453) (358,970)  
Benefit from income taxes 515 7,373 515 20,733  
Loss from discontinued operations $ (1,938) $ (82,376) $ (1,938) $ (338,237)